參附注射液治療感染性休克的臨床療效分析

曹健華

[摘要] 目的 探討參附注射液治療感染性休克的臨床療效。 方法 回顧性分析該院2017年11月—2019年2月收治的56例感染性休克患者的臨床資料?；颊唠S機(jī)分成治療組和對(duì)照組，其中治療組30例，除西醫(yī)常規(guī)治療外加用參附注射液，對(duì)照組26例僅用西醫(yī)常規(guī)治療，不加用參附注射液。觀察并比較兩組的平均動(dòng)脈壓（MAP）、中心靜脈血氧飽和度（ScVO2）、心率（HR）、乳酸（Lac）、ICU住院時(shí)間、病死率以及多器官功能不全發(fā)生率。 結(jié)果 治療24 h后治療組與對(duì)照組平均動(dòng)脈壓（MAP）分別為（72±9.2）mmHg、（66±8.4） mmHg，差異有統(tǒng)計(jì)學(xué)意義（P=0.014<0.05）;中心靜脈血氧飽和度（ScVO2）分別為（86±14.3）%、（75±13.6）%，差異有統(tǒng)計(jì)學(xué)意義（P=0.020<0.05）;心率（HR）分別為（105±10.2）次、（113±12.4）次，差異有統(tǒng)計(jì)學(xué)意義（P=0.011<0.05）;乳酸（Lac）分別為（3.6±0.68）mmol/L、（4.2±0.81）mmol/L，差異有統(tǒng)計(jì)學(xué)意義（P=0.004<0.05）。治療組與對(duì)照組ICU 住院時(shí)間分別為（8.3±2.7）d、（10.1±3.5）d，治療組比對(duì)照組短，差異有統(tǒng)計(jì)學(xué)意義（P=0.034<0.05）。兩組死亡率分別為20.0%、23.1%，差異無(wú)統(tǒng)計(jì)學(xué)意義（P=0.780>0.05）。兩組多器官功能不全發(fā)生率分別為16.7%、42.3%，治療組低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P=0.034<0.05）。 結(jié)論 參附注射液可改善感染性休克患者的微循環(huán)，可以提高感染性休克的治療效果，縮短住院時(shí)間，具有一定的臨床應(yīng)用價(jià)值。

[關(guān)鍵詞] 參附注射液;感染性休克;臨床療效

[中圖分類(lèi)號(hào)] R278? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1674-0742（2019）11（b）-0121-03

[Abstract] Objective To investigate the clinical efficacy of Shenfu injection in the treatment of septic shock. Methods The clinical data of 56 patients with septic shock admitted to the hospital from November 2017 to February 2019 were retrospectively analyzed. The patients were randomly divided into the treatment group and the control group， including 30 patients in the treatment group， except for the conventional treatment of western medicine plus Shenfu injection， and 26 patients in the control group were treated with only Western medicine， and Shenfu injection was not used. Mean arterial pressure （MAP）， central venous oxygen saturation （ScVO2）， heart rate （HR）， lactic acid （Lac）， ICU hospitalization， mortality， and multiple organ dysfunction were observed and compared between the two groups. Results After 24 hours of treatment， the mean arterial pressure （MAP） of the treatment group and the control group were（72±9.2）mmHg and（ 66±8.4 ）mmHg， respectively. The difference was statistically significant （P=0.014<0.05）; central venous oxygen saturation （ScVO2） was （86±14.3）% and （75±13.6）%， respectively， with statistically significant differences （P=0.020<0.05）. Heart rate （HR） was （105±10.2 ）times and （113±12.4） times， respectively， and the difference was statistically significant （P=0.011<0.05）; Lac was （3.6±0.68）mmol/L and （4.2±0.81）mmol/L， respectively， with statistically significant differences （P=0.004<0.05）. The hospital stay in the ICU of the treatment group and the control group were （8.3±2.7）d and （10.1±3.5）d， respectively. The treatment group was shorter than the control group， and the difference was statistically significant （P=0.034<0.05）. The mortality rate of the two groups was 20.0% and 23.1%， respectively， and the difference was not statistically significant （P=0.780>0.05）. The incidence of multiple organ dysfunction in the two groups was 16.7% and 42.3%， respectively. The treatment group was lower than the control group， and the difference was statistically significant （P=0.034<0.05）. Conclusion Shenfu injection can improve the microcirculation of patients with septic shock， improve the therapeutic effect of septic shock， shorten the hospital stay， and have certain clinical application value.